Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) – Investment analysts at SunTrust Banks decreased their FY2019 earnings per share (EPS) estimates for shares of Bellicum Pharmaceuticals in a report issued on Sunday, December 2nd. SunTrust Banks analyst P. Lawson now expects that the biopharmaceutical company will post earnings per share of ($2.26) for the year, down from their previous forecast of ($2.04). SunTrust Banks also issued estimates for Bellicum Pharmaceuticals’ FY2020 earnings at ($2.04) EPS, FY2021 earnings at ($1.37) EPS and FY2022 earnings at ($0.35) EPS.
A number of other equities analysts also recently issued reports on BLCM. Citigroup dropped their price target on Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, August 9th. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 10th. BidaskClub upgraded Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. Finally, Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research note on Friday, November 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Bellicum Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $13.42.
BLCM stock opened at $4.55 on Wednesday. The firm has a market capitalization of $198.16 million, a PE ratio of -1.60 and a beta of 1.10. Bellicum Pharmaceuticals has a 1 year low of $3.88 and a 1 year high of $10.26. The company has a current ratio of 8.01, a quick ratio of 8.01 and a debt-to-equity ratio of 0.39.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.03. The business had revenue of $0.29 million during the quarter, compared to the consensus estimate of $0.07 million.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA lifted its position in Bellicum Pharmaceuticals by 161.4% during the second quarter. BNP Paribas Arbitrage SA now owns 16,949 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 10,466 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Bellicum Pharmaceuticals during the third quarter valued at $110,000. DAFNA Capital Management LLC purchased a new position in Bellicum Pharmaceuticals during the second quarter valued at $221,000. Virtu Financial LLC lifted its position in Bellicum Pharmaceuticals by 266.8% during the third quarter. Virtu Financial LLC now owns 38,673 shares of the biopharmaceutical company’s stock valued at $238,000 after purchasing an additional 28,131 shares in the last quarter. Finally, Jefferies Group LLC lifted its position in Bellicum Pharmaceuticals by 117.9% during the third quarter. Jefferies Group LLC now owns 46,799 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 25,325 shares in the last quarter. Institutional investors own 56.13% of the company’s stock.
In related news, Director Jon P. Stonehouse bought 10,000 shares of the stock in a transaction that occurred on Friday, November 9th. The shares were bought at an average cost of $4.56 per share, for a total transaction of $45,600.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at $45,600. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.84% of the stock is currently owned by insiders.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Recommended Story: Futures Contract
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.